UPCOMING SESSIONS in ET
Thu, Jun 25, 2026
5:00 – 6:00 AM Bangkok
Neurological Manifestations of Amyloidosis — Managing Amyloidosis PN Richard Wlodarski Click To Register
UPCOMING SESSIONS in ET
Thu, Jun 25, 2026 · 5:00 – 6:00 AM Bangkok
Neurological Manifestations of Amyloidosis — Managing Amyloidosis PN
Richard Wlodarski
Click To Register
View all sessions

Clinical Trials and Research

tom-and-josh.jpg
Amyloid Assemblies Once Believed to be Toxic Found to Play Key Role in Muscle Generation
Toxic protein assemblies, or "amyloids," long considered being key drivers in many neuromuscular diseases, also playing a beneficial role in the development of…
Read more
pfizer_logo.jpg
US FDA Accepts Regulatory Submissions for Review of Tafamidis to Treat Transthyretin Amyloid Cardiomyopathy
Pfizer Inc. announced today that the US Food and Drug Administration (FDA) accepted for filing the company's New Drug Applications (NDAs) for tafamidis for the…
Read more
eidos_therapeutics_attribute-cm.jpg
Eidos Therapeutics Initiates ATTRibute-CM, a Phase 3 Study of AG10 in ATTR-CM with Registrational 12-month Endpoint
Eidos Therapeutics, Inc., today announced the initiation and design of its pivotal global Phase 3 trial (ATTRibute-CM) of AG10 in patients with Transthyretin (TTR)…
Read more
Subscribe to